Loading
Weekly cisplatin with doxorubicin before surgery got almost every child with high-risk hepatoblastoma to respond and three quarters to complete removal of the tumour, with three-year survival of 83 percent in a group that previously did poorly.
Prospective single-arm feasibility study of the SIOPEL group in 62 children with high-risk hepatoblastoma (39 with lung metastases): dose-dense cisplatin with doxorubicin before surgery (including transplantation and metastasectomy where needed), then carboplatin and doxorubicin.
60 of 61 evaluable patients had a partial response to pre-operative chemotherapy, 46 (74 percent) had complete resection and 49 (79 percent) were in complete remission at the end of therapy. Three-year event-free survival was 76 percent and overall survival 83 percent at a median follow-up of 52 months; 97 percent had grade 3 or 4 haematological toxicity and 71 percent febrile neutropenia.
Dose-dense cisplatin became the SIOPEL standard for high-risk hepatoblastoma and one arm of the international PHITT trial.
Shares Hepatoblastoma, Doxorubicin, Cisplatin.
Shares Hepatoblastoma, Doxorubicin, Cisplatin.
Shares Hepatoblastoma, Doxorubicin, Cisplatin.
Shares The Lancet Oncology, Carboplatin.
Shares The Lancet Oncology, Cisplatin.
Shares The Lancet Oncology, Cisplatin.
Shares The Lancet Oncology, Doxorubicin.
Shares Hepatoblastoma, Cisplatin, Carboplatin.